BioCentury
ARTICLE | Clinical News

BNC210: Phase II started

May 25, 2015 7:00 AM UTC

Bionomics began a double-blind, 4-way crossover, U.K. Phase II trial to compare 300 and 2,000 mg oral BNC210 vs. placebo or lorazepam in 24 patients. ...